Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Johnson and Johnson
Accenture
Colorcon
Boehringer Ingelheim
US Department of Justice
Cantor Fitzgerald
Argus Health
Teva

Generated: October 23, 2017

DrugPatentWatch Database Preview

Ciprofloxacin hydrochloride; fluocinolone acetonide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ciprofloxacin hydrochloride; fluocinolone acetonide and what is the scope of ciprofloxacin hydrochloride; fluocinolone acetonide freedom to operate?

Ciprofloxacin hydrochloride; fluocinolone acetonide
is the generic ingredient in one branded drug marketed by Laboratorios Salvat and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Ciprofloxacin hydrochloride; fluocinolone acetonide has fifteen patent family members in thirteen countries and two supplementary protection certificates in two countries.

There are thirty-one drug master file entries for ciprofloxacin hydrochloride; fluocinolone acetonide. One supplier is listed for this compound.

Summary for Generic Name: ciprofloxacin hydrochloride; fluocinolone acetonide

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list31
Suppliers / Packagers: see list1
Clinical Trials: see list2,604
Drug Prices:see low prices
DailyMed Link:ciprofloxacin hydrochloride; fluocinolone acetonide at DailyMed

Pharmacology for Ingredient: ciprofloxacin hydrochloride; fluocinolone acetonide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Laboratorios Salvat
OTOVEL
ciprofloxacin hydrochloride; fluocinolone acetonide
SOLUTION/DROPS;OTIC208251-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Laboratorios Salvat
OTOVEL
ciprofloxacin hydrochloride; fluocinolone acetonide
SOLUTION/DROPS;OTIC208251-001Apr 29, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ciprofloxacin hydrochloride; fluocinolone acetonide

Country Document Number Estimated Expiration
European Patent Office2366408► Subscribe
Japan2013521245► Subscribe
Russian Federation2012141641► Subscribe
South Korea20130026430► Subscribe
China102811741► Subscribe
Mexico2012010009► Subscribe
Canada2790652► Subscribe
Japan5744922► Subscribe
Argentina080368► Subscribe
Denmark2366408► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Fuji
Johnson and Johnson
McKinsey
Cipla
Teva
Daiichi Sankyo
Dow
US Army
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot